Literature DB >> 19138479

Treatment of osteochondritis dissecans of the ankle with hyaluronic acid injections: a prospective study.

Omer Mei-Dan1, Guy Maoz, Michael Swartzon, Erol Onel, Beni Kish, Meir Nyska, Gideon Mann.   

Abstract

BACKGROUND: No studies have evaluated the efficacy of hyaluronic acid (HA) in reducing pain caused by osteochondritis dissecans (OCD) of the ankle. We report our initial results with this treatment.
MATERIALS AND METHODS: Fifteen subjects aged 18 to 60 treated for OCD of the talus were followed for 26 weeks, in a pre- and post-treatment repeated measurements design, after receiving three weekly injections of intra-articular HA. The efficacy of HA injections in reducing pain and improving function was assessed at each visit and adverse events were recorded. Efficacy was evaluated by comparing scores determined using a Visual Analog Scale for pain, stiffness and function over time with baseline values. In addition, frequency of symptoms and global function over time were assessed using questionnaires and the AOFAS Ankle-Hindfoot Scale. Data analysis was made using ANCOVA models and paired t-tests. All statistical tests were based on an alpha level of 0.05.
RESULTS: The majority of subjects were male (60%) and had Grade 3 lesions (60%). Mean VAS scores, reported on a scale from 1 (e.g., no pain) to 10 (e.g., worst pain) decreased for pain (5.6 to 3.2), stiffness (5.1 to 2.9), and function (5.9 to 3.3) from baseline to week 26. Subjective global function scores, reported on a scale from 0 to 100 (with 100 representing healthy, pre-injury function), improved on average from 57.3 at baseline to 74.3 by week 26. All of these results were statistically significant, as was the decrease in frequency of pain reported by subjects at the end of the study.
CONCLUSION: OCD of the ankle treated with intra-articular injections of HA caused a decrease in pain scores and increase in global functioning over a short period of time (within 12 weeks) which then lasted for more than 6 months with minimal adverse events.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19138479     DOI: 10.3113/FAI.2008.1171

Source DB:  PubMed          Journal:  Foot Ankle Int        ISSN: 1071-1007            Impact factor:   2.827


  6 in total

Review 1.  Evidence on ankle injections for osteochondral lesions and osteoarthritis: a systematic review and meta-analysis.

Authors:  Angelo Boffa; Davide Previtali; Giorgio Di Laura Frattura; Francesca Vannini; Christian Candrian; Giuseppe Filardo
Journal:  Int Orthop       Date:  2020-07-09       Impact factor: 3.075

2.  Differences Regarding Branded HA in Italy, Part 2: Data from Clinical Studies on Knee, Hip, Shoulder, Ankle, Temporomandibular Joint, Vertebral Facets, and Carpometacarpal Joint.

Authors:  A Migliore; E Bizzi; O De Lucia; A Delle Sedie; S Tropea; M Bentivegna; A Mahmoud; C Foti
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2016-06-07

Review 3.  Diagnosis and treatment of osteochondral lesions of the ankle: current concepts.

Authors:  Marcelo Pires Prado; John G Kennedy; Fernando Raduan; Caio Nery
Journal:  Rev Bras Ortop       Date:  2016-08-17

Review 4.  Hyaluronic acid as an adjunct to microfracture in the treatment of osteochondral lesions of the talus: a systematic review of randomized controlled trials.

Authors:  Julian E Dilley; Joshua S Everhart; Robert G Klitzman
Journal:  BMC Musculoskelet Disord       Date:  2022-04-02       Impact factor: 2.562

5.  Location Distribution of 2,087 Osteochondral Lesions of the Talus.

Authors:  Pascal R van Diepen; Jari Dahmen; J Nienke Altink; Sjoerd A S Stufkens; Gino M M J Kerkhoffs
Journal:  Cartilage       Date:  2020-09-10       Impact factor: 4.634

6.  Treatment of Osteochondral Lesions of the Talus in the Skeletally Immature Population: A Systematic Review.

Authors:  Jari Dahmen; Jason A H Steman; Tristan M F Buck; Peter A A Struijs; Sjoerd A S Stufkens; Christiaan J A van Bergen; Gino M M J Kerkhoffs
Journal:  J Pediatr Orthop       Date:  2022-05-20       Impact factor: 2.537

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.